Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Envveno Medical Corp (NQ: NVNO )

5.980 +0.140 (+2.40%)
Streaming Delayed Price Updated: 10:21 AM EDT, Jul 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Envveno Medical Corp

< Previous 1 2 Next >
enVVeno Medical to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Via ACCESSWIRE
enVVeno Medical Appoints Kevin Belteau as Vice President of Clinical Operations
Via ACCESSWIRE
enVVeno Medical Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Via ACCESSWIRE
enVVeno Medical Announces the Issuance of a New Unique Category III CPT Code Covering the Insertion of a Bioprosthetic Valve into the Femoral Vein
IRVINE, CA / ACCESSWIRE / July 8, 2022 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today... 
From enVVeno Medical Corporation
Via AccessWire
enVVeno Medical Reports First Quarter 2022 Financial Results and Provides Corporate Update
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence. 
From enVVeno Medical Corporation
Via AccessWire
enVVeno Medical Announces New U.S. VenoValve(R) Patent
- Expanding patent portfolio bolsters protection of the Company's lead product -The VenoValve is a potential first-in-class treatment for patients suffering from Chronic Venous Insufficiency (CVI) of... 
From enVVeno Medical Corporation
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
enVVeno Medical Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Update
- Ended the Year With $55 Million in Cash Expected To Fund Operations Through the End of 2024 Including Release of Topline Pivotal Trial Data - Nine (9) VenoValve Surgeries Successfully Completed and... 
From enVVeno Medical Corporation
Via AccessWire
One-Year VenoValve(R) Data Published in Peer-Reviewed Journal, Vascular and Endovascular Surgery
- Previously announced promising results from the first-in-human study demonstrated sustained safety and effectiveness of the VenoValve at 1-year post-implantation - The VenoValve is currently being... 
From enVVeno Medical Corporation
Via AccessWire
Positive Long-Term VenoValve(R) First-in-Human Data Presented at 34th Annual Meeting of the American Venous Forum
- First-in-Human VenoValve recipients continue to benefit from VenoValve at average of 30 months post-surgery - No venous ulcer recurrences, relapses of CVI, or safety issues - Improvements in average... 
From enVVeno Medical Corporation
Via AccessWire
enVVeno Medical Announces ISO 13485 Certification
- Achievement of Quality Management System certification represents an important step towards commercialization IRVINE, CA / ACCESSWIRE / February 16, 2022 / enVVeno Medical Corporation (NASDAQ:NVNO)... 
From enVVeno Medical Corporation
Via AccessWire
enVVeno Medical to Present at the Virtual Investor 2022 Top Picks Conference
Live video webcast presentation on Tuesday, January 25th at 1:00 PM ET IRVINE, CA / ACCESSWIRE / January 20, 2022 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company... 
From enVVeno Medical Corporation
Via AccessWire
JTC Team to Host Virtual Investor 2022 Top Picks Conference on January 25th, 26th, and 27th
- Access the event and schedule of presenting companies at virtualinvestorco.com - - Live video webcast presentations of participating companies followed by interactive Q&A session - PITTSTOWN, NJ /... 
From JTC Team, LLC
Via AccessWire
enVVeno Medical to Present at the Virtual Investor Roundtable Event
- Live moderated video webcast discussion with CEO Robert Berman and Marc Glickman, M.D., Senior Vice President and Chief Medical Officer of enVVeno on Tuesday, November 16th at 1:00 PM ET IRVINE, CA /... 
From enVVeno Medical Corporation
Via AccessWire
enVVeno Medical Reports Third Quarter 2021 Financial Results and Provides Corporate Update
- Quarter marked by corporate rebranding and strategic prioritization of development programs - Company executing on SAVVE U.S pivotal trial evaluating lead product, the VenoValve®, as a potential... 
From enVVeno Medical Corporation
Via AccessWire
JTC Team to Host Virtual Investor Roundtable Event on November 16th, 17th, and 18th
- Access the event and schedule of presenting companies at virtualinvestorco.com - - Live video webcast roundtable discussions with members of Management and Thought Leaders across participating... 
From JTC Team, LLC
Via AccessWire
enVVeno Medical Reports Successful Completion of First VenoValve Surgery for U.S. Pivotal Trial
- 75 Patient Trial Underway to Evaluate Safety and Efficacy of the VenoValve as a Potential Treatment for Severe Deep Venous Chronic Venous Insufficiency (CVI) - Severe CVI Impacts Approximately 2.4... 
From enVVeno Medical Corporation
Via AccessWire
enVVeno Medical Corporation Successfully Completes Rebranding
Company Now Trading Under Ticker Symbol "NVNO" IRVINE, CA / ACCESSWIRE / October 1, 2021 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of... 
From enVVeno Medical Corporation
Via AccessWire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.